Autolus eyes November for potential US approval of Tecartus rival

Autolus Therapeutics is expecting an FDA decision on Nov. 16 for obecabtagene autoleucel (obe-cel), its CAR-T hopeful that would rival Gilead’s Tecartus in adult acute lymphoblastic leukemia.

Executives released the timeline on Monday, noting that they don’t anticipate an FDA advisory committee meeting.

Autolus has touted its CD19-directed CAR-T as…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks